A Kirtava1, S Crudder, A Dilley, C Lally, B Evatt. 1. Division of AIDS, STD, and Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA. akirtava@cdc.gov
Abstract
OBJECTIVE: To assess the management of women with von Willebrand disease( vWD) in an Heamophilia Treatment Center (HTC) setting. METHODS: A total of 75 women with vWd who were registered in HTCs in the United States participated in this study. A telephone interview elicited information about symptoms pertaining to bleeding disorders, diagnostic issues, referral patterns, treatment modalities before and after the enrollment in the HTC, HTC services provided, and satisfaction with care in the HTC. RESULTS: Menorrhagia was the most commonly reported symptom (84%). The average time from the first symptom until clinician recognition was 16 years (range 0-39). In HTC, DDAVP was the most commonly used drug (31%). Of the 75 women, 71 reported a strong positive opinion and satisfaction about their care in the HTCs. DISCUSSION: Women with VWD were typically diagnosed with the condition well into adulthood, in spite of the fact that majority of them experienced several bleeding symptoms beginning in early childhood. In general an HTC setting is appropriate for management of women with bleeding disorders. Diagnosis, treatment and education provided in the HTCs were viewed positively by those surveyed.
OBJECTIVE: To assess the management of women with von Willebrand disease( vWD) in an Heamophilia Treatment Center (HTC) setting. METHODS: A total of 75 women with vWd who were registered in HTCs in the United States participated in this study. A telephone interview elicited information about symptoms pertaining to bleeding disorders, diagnostic issues, referral patterns, treatment modalities before and after the enrollment in the HTC, HTC services provided, and satisfaction with care in the HTC. RESULTS:Menorrhagia was the most commonly reported symptom (84%). The average time from the first symptom until clinician recognition was 16 years (range 0-39). In HTC, DDAVP was the most commonly used drug (31%). Of the 75 women, 71 reported a strong positive opinion and satisfaction about their care in the HTCs. DISCUSSION: Women with VWD were typically diagnosed with the condition well into adulthood, in spite of the fact that majority of them experienced several bleeding symptoms beginning in early childhood. In general an HTC setting is appropriate for management of women with bleeding disorders. Diagnosis, treatment and education provided in the HTCs were viewed positively by those surveyed.
Authors: L V Srivaths; Q C Zhang; V R Byams; J E Dietrich; A H James; P A Kouides; R Kulkarni Journal: Haemophilia Date: 2017-09-05 Impact factor: 4.287
Authors: V R Byams; P A Kouides; R Kulkarni; J R Baker; D L Brown; J C Gill; A M Grant; A H James; B A Konkle; J Maahs; M M Dumas; S McAlister; D Nance; D Nugent; C S Philipp; J M Soucie; E Stang Journal: Haemophilia Date: 2011-07 Impact factor: 4.287
Authors: Claire S Philipp; Ambarina Faiz; John A Heit; Peter A Kouides; Andrea Lukes; Sidney F Stein; Vanessa Byams; Connie H Miller; Roshni Kulkarni Journal: Am J Obstet Gynecol Date: 2011-01-17 Impact factor: 8.661
Authors: E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee Journal: Haemophilia Date: 2013-03 Impact factor: 4.287
Authors: Vanessa R Byams; Britta L Anderson; Althea M Grant; Hani Atrash; Jay Schulkin Journal: Am J Obstet Gynecol Date: 2012-07-16 Impact factor: 8.661
Authors: Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa Journal: Blood Adv Date: 2021-01-12
Authors: Jonathan C Roberts; Lynn M Malec; Imrran Halari; Sarah A Hale; Abiola Oladapo; Robert F Sidonio Journal: Haemophilia Date: 2021-11-10 Impact factor: 4.263